Nachrichten zur Hims & Hers Health Inc. Aktie

Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner (NYSE:LLY)

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is…

Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner

…

DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform

Hims & Hers is expanding access to Eli Lillys branded weight loss drug Zepbound and diabetes drug Mounjaro as well…

Zepbound Now Available Through Hims AND Hers

WEDNESDAY, April 2, 2025 (HealthDay News) -- The telehealth company Hims & Hers Health is expanding its weight-loss offerings by…

Why Hims & Hers Health Stock Couldnt Beat the Market Today

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldnt top the benchmark…

Hims & Hers Stock Rises 5% After Adding Zepbound And Mounjaro To Weight Loss Platform

Hims & Hers Health shares rose 5% Tuesday after announcing it will offer Eli Lilly’s Zepbound and Mounjaro through its…

Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

The digital healthcare platform announced Tuesday that it has added Zepbound and generic liraglutide to its platform…

Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update…

Zepbound now available through Hims & Hers

(HealthDay News) — The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to…

Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…

Why Hims & Hers Health Stock Couldnt Beat the Market Today

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldnt top the benchmark…

‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)

Telehealth platform Hims Hers Health, Inc. ($HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales…

Eli Lilly says it has “no affiliation” with Hims & Hers after market confusion

Hims & Hers investors are clearly antsy about where the company’s weight-loss business is going and Tuesday’s announcement was supposed…

Zepbound Now Available Through Hims & Hers

By I. Edwards HealthDay Reporter WEDNESDAY, April 2, 2025 (HealthDay News) -- The telehealth company Hims & Hers Health is…

Zepbound Now Available Through Hims & Hers

WEDNESDAY, April 2, 2025 (HealthDay News) -- The telehealth company Hims & Hers Health is expanding its weight-loss offerings by…

Hims & Hers Health, Inc. (HIMS): A Bull Case Theory

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on Substack by Antonio Linares. In this…

Hims & Hers Health, Inc. (HIMS): A Bull Case Theory

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on Substack by Antonio Linares. In this article, we…

Hims & Hers Health Aktie: Zepbound-Verkauf bringt kaum Deckungsbeiträge

Charlotte (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse der Bank of America (BofA): Die BofA bestätigt ihre "underperform"-Einschätzung für die Aktie von…

Hims & Hers (HIMS) Stock Climbs as Weight Loss Arsenal Grows with Zepbound Addition

Hims & Hers adds Eli Lillys Zepbound to its platform at $1,899 monthly, boosting its weight loss portfolio…

Hims & Hers to sell Lilly’s weight-loss drug on its telehealth platform

The company said it will expand its weight-loss offerings with branded versions of Lillys tirzepatide.…

Sell Rating for Hims & Hers Health Due to High Pricing and Limited Market Penetration of New Offerings

Daniel Grosslight, an analyst from Citi, maintained the Sell rating on Hims & Hers Health (HIMS – Research Report). The…

Eli Lilly Says It Has No Affiliation With Hims & Hers Regarding Zepbound

Eli Lilly said Tuesday it doesnt have any affiliation with Hims & Hers Health , adding that its weight-loss…

Hims & Hers beginnt mit dem Verkauf von Eli Lilly-Medikamenten zur Gewichtsreduktion

Die FDA hat dem Unternehmen vor kurzem die befristete Erlaubnis zur Herstellung ähnlicher GLP-1-Medikamente entzogen, was einen großen Teil der…

Truist maintains Hims & Hers stock hold rating, $39 target By Investing.com

Truist maintains Hims & Hers stock hold rating, $39 target…

Märkte am Morgen: Zittern vor Trump-Zöllen; Thyssen, LVMH, CoreWeave, Hims & Hers, Ralph Lauren, Tesla

Der DAX hat gestern kräftig zugelegt und den Handelstag bei 22.539 Punkten beendet. Die Vorgaben aus Übersee sind größtenteils positiv.…

Eli Lilly says company has no affiliation with Hims & Hers

In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims hers…

Eli Lilly Has No Affiliation With Hims & Hers

Eli Lilly and Co: * ELI LILLY:…

Hims & Hers health chief legal officer sells $89,863 in stock By Investing.com

Hims & Hers health chief legal officer sells $89,863 in stock…

Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback

Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day,…

Why Hims & Hers Health Stock Soared Tuesday

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up…

Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened? - Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer…

Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it…

Hims & Hers shares rise as company adds new weight-loss medications to platform

Hims & Hers is adding Zepbound, Mounjaro, and the generic injection liraglutide to its platform.…

BofA maintains Hims & Hers stock underperform, $22 target By Investing.com

BofA maintains Hims & Hers stock underperform, $22 target…

Hims & Hers: A Whole-Person Approach to Weight Loss

Hims & Hers Health Inc. (HIMS) shares jumped over 8% to $31.98, hitting a high of $33.70, after announcing expanded…

Hims & Hers to sell Lilly’s Zepbound

Patients can now get a monthly Zepbound prescription through Hims’ telehealth platform.…

Hims & Hers to sell Eli Lillys Zepbound on its platform

Hims & Hers is unable to sell copies of GLP-1 agonists after the FDA declared the shortage of those drugs…

BofA says Hims & Hers Zepbound sales will be ‘immaterial’

BofA keeps an Underperform rating on Hims Hers with a $22 price target after the company indicated it is…

Hims & Hers to sell Lilly’s Zepbound on its telehealth platform

(Reuters) - Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys diabetes and weight-loss…

Hims & Hers to sell Lillys weight-loss drug on its telehealth platform (April 1)

Telehealth firm Hims & Hers Health NYSE:HIMS said on Tuesday it plans to sell Eli Lillys NYSE:LLY weight-loss drug, as…

Hims & Hers to sell Lillys Zepbound on its telehealth platform

Telehealth firm Hims & Hers Health NYSE:HIMS said on Monday it plans to sell Eli Lillys NYSE:LLY diabetes and weight-loss…

Eli Lilly obesity drug on Hims & Hers platform (HIMS:NYSE)

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lillys (LLY) weight loss therapy tirzepatide & generic…

Hims & Hers adding access to generic liraglutide, branded tirzepatide

In a statement posted to the newsroom of Hims Hers (HIMS), Craig Primack stated in part: “In my experience…

Hims & Hers to sell Lillys weight-loss drug on its telehealth platform

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lillys weight-loss drug, as it widens…

Hims & Hers to sell Lillys Zepbound on its telehealth platform

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on its…

Hims & Hers to sell Lillys Zepbound on its telehealth platform

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on its…

Hims & Hers to sell Lilly’s Zepbound on its telehealth platform By Reuters

Hims & Hers to sell Lilly’s Zepbound on its telehealth platform…

Hims & Hers to Sell Lillys Zepbound on Its Telehealth Platform

(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on…

Hims to Sell Lilly’s Zepbound Through Its Telehealth Platform

Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to…

Hims & Hers to Sell Eli Lillys Zepbound via Telehealth Platform, Bloomberg Reports

Price: 31.82, Change: +2.27, Percent Change: +7.68 ...…